Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process
Open Access
- 28 August 2019
- journal article
- research article
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 109 (9) , 639-644
Abstract
Background. Optimal care of patients with inherited bleeding disorders requires that bleeding episodes are treated early, or still better prevented, through extension of patient care beyond hospital-based treatment to home-based therapy. In South Africa (SA), adoption of home therapy is variable, in part owing to lack of consensus among healthcare providers on what constitutes home therapy, which patients should be candidates for it, how it should be monitored, and what the barriers to home therapy are. Objectives. To conduct a modified Delphi process in order to establish consensus on home therapy among haemophilia healthcare providers in SA. Methods. Treaters experienced in haemophilia care were invited to participate in a consensus-seeking process conducted in three rounds. In round 1, provisional statements around home therapy were formulated as questions and collated in a structured list. In rounds 2 and 3, evolving versions of the questionnaire were administered to participants. Consensus was defined as ≥70% agreement among the participants. Results. The panel composition included an equal number of physicians and non-physicians. The participation rate was 100% through all three consensus rounds. The group reached consensus for 92% of the statements. Consensus of 100% was reached on starting home therapy in paediatric patients, requiring all patients on home therapy to sign informed consent and indemnity, and providing round-the-clock support for patients on home therapy. Conclusions. The home therapy consensus statements in this report have the potential to translate to policy on home therapy and to guide the initiation, practice and evaluation of home therapy programmes in SA.Keywords
This publication has 33 references indexed in Scilit:
- Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in SwedenJournal of Medical Economics, 2017
- Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United StatesValue in Health, 2016
- Efmoroctocog Alfa: A Review in Haemophilia ADrugs, 2016
- The burden of bleeding in haemophilia: is one bleed too many?Haemophilia, 2014
- Increased burden on caregivers of having a child with haemophilia complicated by inhibitorsPediatric Blood & Cancer, 2013
- Switching clotting factor concentrates: considerations in estimating the risk of immunogenicityHaemophilia, 2013
- Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD studyHealth Policy, 2012
- Delphi: myths and realityJournal of Health Organization and Management, 2003
- Home‐based factor infusion therapy and hospitalization for bleeding complications among males with haemophiliaHaemophilia, 2001
- Hæmophilia and Home TherapyThe Lancet, 1979